[Efficacy and safety of adenosine triphosphate in the control of supraventricular paroxysmal tachycardia].
Our purpose was to assess the efficacy and safety of intravenous ATP for the acute termination of paroxysmal supraventricular tachycardia. There were 14 women and 10 men, aged 38 +/- 15 years. Three patients had evidence of structural heart disease (Ebstein's anomaly associated to atrial septal defect, operated mitral stenosis with insertion of a mechanical heart valve and CAD respectively). Twelve patients had Wolff-Parkinson-White syndrome and another had undergone surgical ablation of an accessory pathway. At the time of electrophysiologic testing, ATP was administered during episodes of paroxysmal supraventricular tachycardia, via a central vein, in incremental doses of 5, 10 and 20 mg followed by a flush of 10 c.c. of isotonic saline. The mechanism of the arrhythmia was orthodromic AV reentrant tachycardia in 19 (79%), AV nodal reentrant tachycardia in 4 (16.6%) and atrial tachycardia in one patient. The mean frequency of the tachycardia was 174 +/- 33 b.p.m. A dose of 5 mg was effective in 16 patients (66%), 5 required 10 mg and two required 20 mg for termination of the tachycardia. In the patient with atrial tachycardia ATP was not effective. The average time after injection to termination of the arrhythmia was 16 +/- 8 seconds. Orthodromic AV reentrant tachycardia was interrupted in the AV node limb in all but one patient and AV nodal reentry was terminated in the "slow-pathway" in three of the four patients. Nine patients had premature ventricular complexes, isolated or in couplets, after the termination of the SVT. Three patients had immediate recurrence of the SVT.(ABSTRACT TRUNCATED AT 250 WORDS)
Brandão
L
L
Serviço de Cardiologia, Hospital de Santa Maria, Lisboa.
de Sousa
J
J
Barreiros
M C
MC
Vagueiro
M C
MC
Amram
S S
SS
D000255:Adenosine Triphosphate / Q000627:therapeutic use*; D000328:Adult; D004562:Electrocardiography; D004594:Electrophysiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013614:Tachycardia, Paroxysmal / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D013617:Tachycardia, Supraventricular / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
D000255:Adenosine Triphosphate
Eficácia e segurança do trifosfato de adenosina na terminação de taquicardia paroxística supraventricular.